Thiazolidinedione drugs and cardiovascular risks: a science advisory from the American Heart Association and American College of Cardiology Foundation.

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Circulation

• Publication date

  2010-04-27

• Fields of study

  Medicine

• Identifiers
  DOI 10.1161/CIR.0b013e3181d34114PMID 20179252
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• What is the European Medicines Agency?

  2012cited by this paper
• [The BARI 2D study].

  2010cited by this paper
• Thiazolidinediones and Cardiovascular Events in Patients with Type 2 Diabetes Mellitus

  2009cited by this paper
• Intensive Glycemic Control and the Prevention of Cardiovascular Events: Implications of the ACCORD, ADVANCE, and VA Diabetes Trials

  2009cited by this paper
• Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial.

  2009cited by this paper
• A randomized trial of therapies for type 2 diabetes and coronary artery disease.

  2009cited by this paper
• Rosiglitazone and Myocardial Infarction in Patients Previously Prescribed Metformin

  2009cited by this paper
• Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy: A Consensus Statement of the American Diabetes Association and the European Association for the Study of Diabetes

  2009cited by this paper
• Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy

  2009cited by this paper
• Adverse cardiovascular events during treatment with pioglitazone and rosiglitazone: population based cohort study

  2009cited by this paper
• Glucose control and vascular complications in veterans with type 2 diabetes.

  2009cited by this paper
• Effects of Intensive Glucose Lowering in Type 2 Diabetes

  2009cited by this paper
• Intensive glycemic control and the prevention of cardiovascular events:implications of the ACCORD,ADVANCE,and VA Diabetes Trials

  2009cited by this paper
• 10-year follow-up of intensive glucose control in type 2 diabetes.

  2008cited by this paper
• Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes

  2008cited by this paper
• Comparison of cardiovascular outcomes in elderly patients with diabetes who initiated rosiglitazone vs pioglitazone therapy.

  2008cited by this paper
• A Comparison of Select Cardiovascular Outcomes by Antidiabetic Prescription Drug Classes Used to Treat Type 2 Diabetes Among Military Health System Beneficiaries, Fiscal Year 2003-2006

  2008cited by this paper
• Effects of intensive glucose lowering in type 2 diabetes.

  2008cited by this paper
• Effects of Intensive Glucose Lowering in Type 2 Diabetes The Action to Control Cardiovascular Risk in Diabetes Study Group

  2008cited by this paper
• Rosiglitazone evaluated for cardiovascular outcomes – an interim analysis

  2007cited by this paper
• Cardiovascular safety of rosiglitazone.

  2007cited by this paper
• The record on rosiglitazone and the risk of myocardial infarction.

  2007cited by this paper
• Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials.

  2007cited by this paper
• Rosiglitazone evaluated for cardiovascular outcomes--an interim analysis.

  2007cited by this paper
• Rosiglitazone for type 2 diabetes mellitus.

  2007cited by this paper
• A comparison of pioglitazone and rosiglitazone for hospitalization for acute myocardial infarction in type 2 diabetes

  2007cited by this paper
• Uncertain Effects of Rosiglitazone on the Risk for Myocardial Infarction and Cardiovascular Death

  2007cited by this paper
• Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials.

  2007cited by this paper
• Coronary heart disease outcomes in patients receiving antidiabetic agents

  2007cited by this paper
• Rosiglitazone: A Thunderstorm from Scarce and Fragile Data

  2007cited by this paper
• Thiazolidinediones and cardiovascular outcomes in older patients with diabetes.

  2007cited by this paper
• A randomized, placebo-controlled trial assessing the effects of rosiglitazone on echocardiographic function and cardiac status in type 2 diabetic patients with New York Heart Association Functional Class I or II Heart Failure.

  2007cited by this paper
• The rosiglitazone story--lessons from an FDA Advisory Committee meeting.

  2007cited by this paper
• Rosiglitazone for type 2 diabetes mellitus.

  2007cited by this paper
• Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis.

  2007cited by this paper
• Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes.

  2007cited by this paper
• Fixed vs random effects meta‐analysis in rare event studies: The Rosiglitazone link with myocardial infarction and cardiac death

  2007cited by this paper
• AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute.

  2006cited by this paper
• AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update endorsed by the National Heart, Lung, and Blood Institute.

  2006cited by this paper
• Epidemic obesity and type 2 diabetes in Asia.

  2006cited by this paper
• Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial.

  2005cited by this paper
• A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia.

  2005cited by this paper
• Effects of Angiotensin Converting Enzyme Inhibition in Patients With Stable Coronary Artery Disease: The Prevention of Events With Angiotensin Converting Enzyme Inhibition (PEACE) Trial: The PEACE Study Investigators

  2005cited by this paper
• Thiazolidinediones.

  2004cited by this paper
• Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association: response to Nesto.

  2004cited by this paper
• Thiazolidinedione Use, Fluid Retention, and Congestive Heart Failure: A Consensus Statement From the American Heart Association and American Diabetes Association

  2003cited by this paper
• Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. October 7, 2003.

  2003cited by this paper
• Predictors of subsequent coronary events, stroke, and death among survivors of first hospitalized myocardial infarction.

  2002cited by this paper
• Glucose metabolism in patients with acute myocardial infarction and no previous diagnosis of diabetes mellitus: a prospective study.

  2002cited by this paper
• 胰岛素增敏剂一Thiazolidinediones研究现状

  2000cited by this paper
• Predictors of congestive heart failure in the elderly: the Cardiovascular Health Study.

  2000cited by this paper
• Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.

  1998cited by this paper
• Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34)

  1998cited by this paper
• Risk Variable Clustering in the Insulin Resistance Syndrome: The Framingham Offspring Study

  1997cited by this paper
• Global Estimates for Prevalence of Diabetes Mellitus and Impaired Glucose Tolerance in Adults

  1993cited by this paper

• Enzymes of the outer mitochondrial membrane regulating cholesterol and fatty acid metabolism in cancer.

  2025cites this paper
• Prevention and Management of Heart Failure Associated with Type 2 Diabetics in Rural Australia

  2025cites this paper
• Anti-Hyperglycemic Medication Management in the Perioperative Setting: A Review and Illustrative Case of an Adverse Effect of GLP-1 Receptor Agonist

  2024cites this paper
• Effect of combination pioglitazone with sodium‐glucose cotransporter‐2 inhibitors or glucagon‐like peptide‐1 receptor agonists on outcomes in type 2 diabetes: A systematic review, meta‐analysis, and real‐world study from an international federated database

  2024cites this paper
• Protective Role of the Podocyte IL-15 / STAT5 Pathway in Focal Segmental Glomerulosclerosis

  2024cites this paper
• Treatment of type 2 diabetes patients with heart conditions

  2023cites this paper
• Predicting and preventing heart failure in type 2 diabetes.

  2023cites this paper
• Cardiovascular benefit of SGLT2 inhibitors

  2021cites this paper
• The pleiotropic peroxisome proliferator activated receptors: Regulation and therapeutics.

  2021cites this paper
• Diabetes Management in Patients with Heart Failure

  2021cites this paper
• Optimale medikamentöse Therapie bei Typ‑2-Diabetikern mit einer koronaren Herzerkrankung – Update 2021

  2021cites this paper
• Evolution of Type 2 Diabetes Management from a Glucocentric Approach to Cardio-Renal Risk Reduction: The New Paradigm of Care

  2021cites this paper
• Key Characteristics of Cardiovascular Toxicants

  2021cites this paper
• PPARs and Myocardial Infarction

  2020cites this paper
• Soluble (pro)renin receptor treats metabolic syndrome in mice with diet-induced obesity via interaction with PPARγ.

  2020cites this paper
• The Glitazars Paradox: Cardiotoxicity of the Metabolically Beneficial Dual PPARα and PPARγ Activation.

  2020cites this paper
• Cost-effectiveness of empagliflozin compared with liraglutide based on cardiovascular outcome trials in Type II diabetes.

  2020cites this paper
• STUDY ON SAFETY OF INSULIN ADD ON THERAPY AND ORAL HYPOGLYCEMIC AGENTS (OHGAs) IN TYPE - II DIABETES PATIENTS

  2020cites this paper
• Effects of naringenin on vascular changes in prolonged hyperglycaemia in fructose-STZ diabetic rat model.

  2019cites this paper
• Type 2 Diabetes Mellitus and Heart Failure: A Scientific Statement From the American Heart Association and the Heart Failure Society of America.

  2019cites this paper
• Thiazolidinediones: the Forgotten Diabetes Medications

  2019cites this paper
• Type 2 Diabetes Mellitus and Heart Failure, A Scientific Statement From the American Heart Association and Heart Failure Society of America.

  2019cites this paper
• Dual peroxisome-proliferator-activated-receptor-α/γ activation inhibits SIRT1-PGC1α axis and causes cardiac dysfunction.

  2019cites this paper
• Perspective Review: Type 2 Diabetes and Readmission for Heart Failure

  2018cites this paper
• Cardiovascular Safety of Antihyperglycemic Agents: “Do Good or Do No Harm”

  2018cites this paper
• Novel pharmacological targets for calcific aortic valve disease: Prevention and treatments

  2018cites this paper
• Thiazolidinediones Cause Cardiotoxicity via PPARγ- Independent Mechanism

  2018cites this paper
• Ventricular myocyte sarcolemmal Kir6.1/SUR2B potassium channels; A potential effector of cardioprotection

  2018cites this paper
• Pharmacological Prevention of Cardiovascular Outcomes in Diabetes Mellitus: Established and Emerging Agents

  2018cites this paper
• Safety of diabetes drugs in patients with heart failure.

  2017cites this paper
• Glucose‐lowering drugs

  2017cites this paper
• Characterization of alendronic- and undecylenic acid coated magnetic nanoparticles for the targeted delivery of rosiglitazone to subcutaneous adipose tissue.

  2017cites this paper
• Safety of diabetes drugs in patients with heart failure.

  2017cites this paper
• Learning diseases from data : a disease space odyssey

  2017cites this paper
• Pioglitazone, a PPARγ agonist, attenuates PDGF-induced vascular smooth muscle cell proliferation through AMPK-dependent and AMPK-independent inhibition of mTOR/p70S6K and ERK signaling.

  2016cites this paper
• Design of reprogrammed neuronal transplantation and nanobiomaterial-based microglial therapeutic technologies for management of Parkinson's disease

  2016cites this paper
• Contributory Risk and Management of Comorbidities of Hypertension, Obesity, Diabetes Mellitus, Hyperlipidemia, and Metabolic Syndrome in Chronic Heart Failure: A Scientific Statement From the American Heart Association.

  2016cites this paper
• Cyclic Stretch Facilitates Myogenesis in C2C12 Myoblasts and Rescues Thiazolidinedione-Inhibited Myotube Formation

  2016cites this paper
• Type 2 Diabetes and Heart Failure: Challenges and Solutions

  2016cites this paper
• Assessing Risks of Glucose Lowering Therapy in Heart Failure: Should We Rely on Post-hoc Analyses?

  2016cites this paper
• Context-dependent effects of dipeptidyl peptidase 4 inhibitors

  2016cites this paper
• Clinically and pharmacologically relevant interactions of antidiabetic drugs

  2016cites this paper
• SAFETY OF INSULIN ADD ON THERAPY AND ORAL HYPOGLYCEMIC AGENTS (OHGAs) POLYPHARMACY IN TYPE - II DIABETES PATIENTS - A PROSPECTIVE OBSERVATIONAL STUDY

  2015cites this paper
• PPARs: Protectors or Opponents of Myocardial Function?

  2015cites this paper
• Metformin and metabolic diseases: a focus on hepatic aspects

  2015cites this paper
• Maintaining ancient organelles: mitochondrial biogenesis and maturation.

  2015cites this paper
• Evaluation and Management of the Newly Diagnosed Patient with Type-2 Diabetes

  2015cites this paper
• Pioglitazone, a peroxisome proliferator-activated receptor &ggr; activator, suppresses coronary spasm

  2014cites this paper
• A systems biology approach to understand the pathophysiological mechanisms of cardiac pathological hypertrophy associated with rosiglitazone

  2014cites this paper
• Evaluating Cardiovascular Safety of Novel Therapeutic Agents for the Treatment of Type 2 Diabetes Mellitus

  2014cites this paper
• Indian Journal of Pharmacy Practice Association of Pharmaceutical Teachers of India A Retrospective Evaluation of the use of Thiazolidinediones in Patients with Diabetes Mellitus in a Private Hospital in Ras

  2014cites this paper
• the American Heart Association and American College of Cardiology Foundation Coronary and Other Atherosclerotic Vascular Disease: 2011 Update: A Guideline From AHA/ACCF Secondary Prevention and Risk Reduction Therapy for Patients With

  2014cites this paper
• [Cardiovascular effects and safety of glucose-lowering drugs: current situation].

  2014cites this paper
• Treatment with thiazolidinediones

  2013cites this paper
• Risk of Stroke with Thiazolidinediones: A Ten-Year Nationwide Population-Based Cohort Study

  2013cites this paper
• Setting the record straight on TIDE: a lost opportunity for patients with diabetes

  2013cites this paper
• Reversible inhibition of vasoconstriction by thiazolidinediones related to PI3K/Akt inhibition in vascular smooth muscle cells.

  2013cites this paper
• Pioglitazone Attenuates Valvular Calcification Induced by Hypercholesterolemia

  2013cites this paper
• Pioglitazone Improves Reversal Learning and Exerts Mixed Cerebrovascular Effects in a Mouse Model of Alzheimer’s Disease with Combined Amyloid-β and Cerebrovascular Pathology

  2013cites this paper
• KLF11 mediates PPARγ cerebrovascular protection in ischaemic stroke.

  2013cites this paper
• Effects of pioglitazone on cardiac ion currents and action potential morphology in canine ventricular myocytes.

  2013cites this paper
• A new “Comparative Effectiveness” assessment strategy using the THIN database: comparison of the cardiac complications of pioglitazone and rosiglitazone

  2013cites this paper
• The ‘collateral benefits‘ of noninsulin therapies for Type 2 diabetes

  2013cites this paper
• Suppression of Primary Aldosteronism and Resistant Hypertension by the Peroxisome Proliferator-activated Receptor Gamma Agonist Pioglitazone

  2013cites this paper
• Peroxisome Proliferator–Activated Receptor-&ggr; Activation Prevents Sepsis-Related Cardiac Dysfunction and Mortality In Mice

  2013cites this paper
• Pioglitazone improves glucose metabolism and modulates skeletal muscle TIMP-3–TACE dyad in type 2 diabetes mellitus: a randomised, double-blind, placebo-controlled, mechanistic study

  2013cites this paper
• Emerging therapies for residual risk.

  2012cites this paper
• A Retrospective Evaluation of the use of Thiazolidinediones in Patients with Diabetes Mellitus in a Private Hospital in Ras Al Khaimah.

  2012cites this paper
• Insulin Resistance, Metabolic Syndrome, and Therapy

  2012cites this paper
• Determinants of evolving metabolic and cardiovascular benefit/risk profiles of rosiglitazone therapy during the natural history of diabetes: molecular mechanisms in the context of integrated pathophysiology.

  2012cites this paper
• Glitazones in chronic kidney disease: potential and concerns.

  2012cites this paper
• Selective block of KATP channels: why the anti‐diabetic sulphonylureas and rosiglitazone have more in common than we thought

  2012cites this paper
• Rosiglitazone, Myocardial Ischemic Risk, and Recent Regulatory Actions

  2012influential citation
• Applications of metabolomics for understanding the action of peroxisome proliferator-activated receptors (PPARs) in diabetes, obesity and cancer

  2012cites this paper
• Modulation of baroreflex function by rosiglitazone in prediabetic hyperglycemic rats.

  2012cites this paper
• Long-term prognosis of patients with acute myocardial infarction in the era of acute revascularization (from the Heart Institute of Japan Acute Myocardial Infarction [HIJAMI] registry).

  2012cites this paper
• Body Fat Distribution and Risk of Cardiovascular Disease: An Update

  2012cites this paper
• Diabetes mellitus and the heart

  2012cites this paper
• Screening for adiponectin secretion regulators.

  2012cites this paper
• Interplay between statins and PPARs in improving cardiovascular outcomes: a double‐edged sword?

  2012cites this paper
• Evolving Therapeutic Options for Type 2 Diabetes Mellitus: An Overview

  2012cites this paper
• Effect of Thiazolidinedione Treatment on Proteinuria and Renal Hemodynamic in Type 2 Diabetic Patients with Overt Nephropathy

  2012cites this paper
• Thiazolidinediones: a long way to clinical practice

  2011cites this paper
• Diabetes und Herz

  2011cites this paper
• Cannabidiol as an emergent therapeutic strategy for lessening the impact of inflammation on oxidative stress.

  2011cites this paper
• Cytochrome P450-mediated cardiovascular drug interactions

  2011cites this paper
• Design, history and results of the Thiazolidinedione Intervention with vitamin D Evaluation (TIDE) randomised controlled trial

  2011cites this paper
• Pleiotropic Effects of Glitazones: A Double Edge Sword?

  2011cites this paper
• Concomitant oral antihyperglycemic agent use and associated treatment outcomes after initiation of insulin therapy.

  2011cites this paper
• Effects of specific chemical suppressors of plasminogen activator inhibitor-1 in cardiovascular diseases

  2011cites this paper
• Comparison of quantity of left ventricular scarring and remodeling by magnetic resonance imaging in patients with versus without diabetes mellitus and with coronary artery disease.

  2011cites this paper
• Rosiglitazone does not improve vascular function in subjects with chronic kidney disease.

  2011cites this paper
• Clinical practice and implications of recent diabetes trials

  2011cites this paper
• Thiazolidinediones and the risk of incident congestive heart failure among patients with type 2 diabetes mellitus

  2011cites this paper
• Effects of rosiglitazone on the configuration of action potentials and ion currents in canine ventricular cells

  2011cites this paper
• PPARγ activation induces acute PAI-1 gene expression in the liver but not in adipose tissues of diabetic model mice.

  2011cites this paper
• A randomized‐controlled trial to investigate the effects of rivoglitazone, a novel PPAR gamma agonist on glucose–lipid control in type 2 diabetes

  2011cites this paper
• Disorders of fat partitioning in treated HIV-infection.

  2011cites this paper
• Thiazolidinediones and congestive heart failure in veterans with type 2 diabetes

  2011cites this paper
• AHA/ACCF Secondary Prevention and Risk Reduction Therapy for Patients with Coronary and other Atherosclerotic Vascular Disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation.

  2011cites this paper